全文获取类型
收费全文 | 13318篇 |
免费 | 604篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 274篇 |
妇产科学 | 139篇 |
基础医学 | 1790篇 |
口腔科学 | 406篇 |
临床医学 | 839篇 |
内科学 | 2998篇 |
皮肤病学 | 284篇 |
神经病学 | 1065篇 |
特种医学 | 603篇 |
外科学 | 2427篇 |
综合类 | 81篇 |
预防医学 | 331篇 |
眼科学 | 326篇 |
药学 | 883篇 |
中国医学 | 23篇 |
肿瘤学 | 1423篇 |
出版年
2023年 | 75篇 |
2021年 | 228篇 |
2020年 | 137篇 |
2019年 | 186篇 |
2018年 | 241篇 |
2017年 | 171篇 |
2016年 | 230篇 |
2015年 | 241篇 |
2014年 | 351篇 |
2013年 | 437篇 |
2012年 | 658篇 |
2011年 | 723篇 |
2010年 | 385篇 |
2009年 | 307篇 |
2008年 | 584篇 |
2007年 | 668篇 |
2006年 | 599篇 |
2005年 | 629篇 |
2004年 | 633篇 |
2003年 | 599篇 |
2002年 | 611篇 |
2001年 | 411篇 |
2000年 | 413篇 |
1999年 | 356篇 |
1998年 | 170篇 |
1997年 | 132篇 |
1996年 | 131篇 |
1995年 | 131篇 |
1994年 | 114篇 |
1993年 | 112篇 |
1992年 | 249篇 |
1991年 | 282篇 |
1990年 | 238篇 |
1989年 | 325篇 |
1988年 | 227篇 |
1987年 | 209篇 |
1986年 | 199篇 |
1985年 | 197篇 |
1984年 | 128篇 |
1983年 | 129篇 |
1982年 | 70篇 |
1979年 | 97篇 |
1978年 | 65篇 |
1977年 | 66篇 |
1974年 | 73篇 |
1973年 | 68篇 |
1972年 | 72篇 |
1971年 | 60篇 |
1970年 | 65篇 |
1969年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
2.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
3.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
4.
5.
6.
Hirokazu Miki Shingen Nakamura Masahiro Oura Hirofumi Hamano Kenji Ikuta Naoto Okada Yasunobu Okamoto Kimiko Sogabe Mamiko Takahashi Masami Iwasa Kengo Udaka Takeshi Harada Kiyoe Kurahashi Shiro Fujii Sumiko Yoshida Kumiko Kagawa Itsuro Endo Ken-ichi Aihara Masahiro Abe 《British journal of haematology》2019,186(2):355-358
7.
Ryuichi Iwakiri Kiyohito Tanaka Takuji Gotoda Shiro Oka Takao Ohtsuka Yasuhisa Sakata Toshimi Chiba Kazuhide Higuchi Hironori Masuyama Ryoichi Nozaki Koji Matsuda Nobuyuki Shimono Kazuma Fujimoto Hisao Tajiri 《Digestive endoscopy》2019,31(5):477-497
As part of the activities toward standardizing endoscopy procedures, the Japan Gastroenterological Endoscopy Society has prepared guidelines for cleansing and disinfection of gastrointestinal endoscopes. The environment of gastrointestinal endoscopy differs between Japan and advanced Western countries. In advanced Western countries, gastrointestinal endoscopy is performed almost exclusively at specialized facilities, where strict provisions are observed for cleansing and disinfecting endoscopes. In Japan, however, gastrointestinal endoscopy is performed even in small clinics, and the annual number of gastrointestinal endoscopy cases is enormous. In addition, the method for cleansing and disinfecting endoscopes differs among hospitals. Although there is a distinct lack of evidence for how gastrointestinal endoscopes are cleaned and disinfected, it is necessary to standardize the method for doing so to advance the field of endoscopic medicine. 相似文献
8.
9.
10.
Osteoblasts are the only cells that can give rise to bones in vertebrates. Thus, one of the most important functions of these metabolically active cells is mineralized matrix production. Because osteoblasts have a limited lifespan, they must be constantly replenished by preosteoblasts, their immediate precursors. Because disruption of the regulation of bone-forming osteoblasts results in a variety of bone diseases, a better understanding of the origin of these cells by defining the mechanisms of bone development, remodeling, and regeneration is central to the development of novel therapeutic approaches. In recent years, substantial new insights into the origin of osteoblasts—largely owing to rapid technological advances in murine lineage-tracing approaches and other single-cell technologies—have been obtained. Collectively, these findings indicate that osteoblasts involved in bone formation under various physiological, pathological, and therapeutic conditions can be obtained from numerous sources. The origins of osteoblasts include, but are not limited to, chondrocytes in the growth plate, stromal cells in the bone marrow, quiescent bone-lining cells on the bone surface, and specialized fibroblasts in the craniofacial structures, such as sutures and periodontal ligaments. Because osteoblasts can be generated from local cellular sources, bones can flexibly respond to regenerative and anabolic cues. However, whether osteoblasts derived from different cellular sources have distinct functions remains to be investigated. Currently, we are at the initial stage to aptly unravel the incredible diversity of the origins of bone-forming osteoblasts. © 2021 American Society for Bone and Mineral Research (ASBMR). 相似文献